Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model

The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model...

Descripción completa

Detalles Bibliográficos
Autores principales: Driouich, Jean-Sélim, Bernadin, Ornéllie, Touret, Franck, de Lamballerie, Xavier, Nougairède, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191698/
https://www.ncbi.nlm.nih.gov/pubmed/37207822
http://dx.doi.org/10.1016/j.antiviral.2023.105638
_version_ 1785043507426099200
author Driouich, Jean-Sélim
Bernadin, Ornéllie
Touret, Franck
de Lamballerie, Xavier
Nougairède, Antoine
author_facet Driouich, Jean-Sélim
Bernadin, Ornéllie
Touret, Franck
de Lamballerie, Xavier
Nougairède, Antoine
author_sort Driouich, Jean-Sélim
collection PubMed
description The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against these Omicron variants in vivo. Our results show that at exposures consistent with those observed in humans, Sotrovimab remains active against BQ.1.1 and XBB.1, although for BQ.1.1 the efficacy is lower than that observed against the first globally dominant Omicron sublineages BA.1 and BA.2.
format Online
Article
Text
id pubmed-10191698
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-101916982023-05-18 Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model Driouich, Jean-Sélim Bernadin, Ornéllie Touret, Franck de Lamballerie, Xavier Nougairède, Antoine Antiviral Res Article The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model to determine whether Sotrovimab retains antiviral activity against these Omicron variants in vivo. Our results show that at exposures consistent with those observed in humans, Sotrovimab remains active against BQ.1.1 and XBB.1, although for BQ.1.1 the efficacy is lower than that observed against the first globally dominant Omicron sublineages BA.1 and BA.2. The Authors. Published by Elsevier B.V. 2023-07 2023-05-18 /pmc/articles/PMC10191698/ /pubmed/37207822 http://dx.doi.org/10.1016/j.antiviral.2023.105638 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Driouich, Jean-Sélim
Bernadin, Ornéllie
Touret, Franck
de Lamballerie, Xavier
Nougairède, Antoine
Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
title Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
title_full Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
title_fullStr Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
title_full_unstemmed Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
title_short Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
title_sort activity of sotrovimab against bq.1.1 and xbb.1 omicron sublineages in a hamster model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191698/
https://www.ncbi.nlm.nih.gov/pubmed/37207822
http://dx.doi.org/10.1016/j.antiviral.2023.105638
work_keys_str_mv AT driouichjeanselim activityofsotrovimabagainstbq11andxbb1omicronsublineagesinahamstermodel
AT bernadinornellie activityofsotrovimabagainstbq11andxbb1omicronsublineagesinahamstermodel
AT touretfranck activityofsotrovimabagainstbq11andxbb1omicronsublineagesinahamstermodel
AT delamballeriexavier activityofsotrovimabagainstbq11andxbb1omicronsublineagesinahamstermodel
AT nougairedeantoine activityofsotrovimabagainstbq11andxbb1omicronsublineagesinahamstermodel

Ejemplares similares